Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus By Reuters
By Deena Beasley SAN FRANCISCO (Reuters) - An experimental Alzheimer's disease drug from Eisai and Biogen (NASDAQ:BIIB) slowed cognitive decline in a closely-watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. The drug,…
#deenabeasley #lecanemab #alzheimer #eisai #alzheimerdisease #brain #drug #disease #beasley #deena